Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 3,541 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infant Clear all
Completed Not applicable Interventional

Role of Macronutrient Diet Composition and Infant Metabolic Outcomes in Gestational Diabetes

NCT01719029
View directory record Official record
Conditions
Gestational Diabetes Mellitus
Interventions
Low-Carbohydrate/Higher Fat Diet, High Carbohydrate/Low fat diet
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 10, 2015 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Not applicable Interventional Results available

Open-label Vitamin D Trial for Patients With Cystic Fibrosis and Allergic Bronchopulmonary Aspergillosis

NCT01222273
View directory record Official record
Conditions
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
Interventions
cholecalciferol (Vitamin D3)
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 21, 2026, 7:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Maternal Sleep and Mental Health

NCT06544941
View directory record Official record
Conditions
Postpartum Depression, Postpartum Anxiety, Sleep Disturbance, Infant Behavior, Maternal Behavior, Inflammation, Military Family
Interventions
Smart Bassinet, HALO
Device
Lead sponsor
University of Colorado, Colorado Springs
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
342 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Colorado Springs, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate Safety, Reactogenicity and Immunogenicity of GSK Biologicals' RSV Investigational Vaccine Based on Viral Proteins Encoded by Chimpanzee-derived Adenovector (ChAd155-RSV) (GSK3389245A) in RSV-seropositive Infants

NCT02927873
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A) middle dose formulation vaccine, RSV (GSK3389245A) high dose formulation vaccine, Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 23 Months
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
6
States / cities
Anaheim, California • Aurora, Colorado • Topeka, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia

NCT00477594
View directory record Official record
Conditions
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions
mipomersen sodium
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Chicago, Illinois • Auburn, Maine • Biddeford, Maine + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Aztreonam for Inhalation Solution (AZLI) in a Continuous Alternating Therapy Regimen for the Treatment of Chronic Pseudomonas Aeruginosa Infection in Patients With CF

NCT01641822
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
AZLI, Placebo to match AZLI, Tobramycin inhalation solution
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
71
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 62 more
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 21, 2026, 7:32 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Using NICU Discharge Education Tools to Enhance Discharge Preparation for Parents of Moderate to Late Preterm Infants

NCT06177951
View directory record Official record
Conditions
Discharge Readiness
Interventions
NICU Discharge Passport, NICU Infant Care Class
Other
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Queens, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children

NCT01893554
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV ΔNS2 Δ1313 I1314L Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Months to 59 Months
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Completed No phase listed Observational

Intrapartum Epidural Fentanyl/Bupivacaine Analgesia, Infant Feeding Behavior, & Breast-Feeding Outcomes

NCT01260051
View directory record Official record
Conditions
Anesthesia, Epidural, Breast Feeding
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
310 participants
Timeline
2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 21, 2026, 7:32 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Prenatal Transplantation for Fetuses With Fanconi Anemia

NCT07408583
View directory record Official record
Conditions
Fanconi Anemia, Anemia, Hypoplastic, Congenital, Congenital Bone Marrow Failure Syndromes, Bone Marrow Failure Disorders, Genetic Diseases, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Repair-Deficiency Disorders, Cancer Predisposition Syndrome
Interventions
IUHSCT for FA-affected fetuses
Biological
Lead sponsor
Agnieszka Czechowicz
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2033
U.S. locations
2
States / cities
San Francisco, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Adherence With Iron Sprinkles Among High-Risk Infants

NCT00136266
View directory record Official record
Conditions
Anemia, Iron Deficiency
Interventions
Ferrous sulphate drops with vitamins A, D, and C, Ferrous fumarate sprinkles with vitamins and minerals
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
5 Months to 7 Months
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

NCT05033080
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
69
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Weigh Easy: Simplifying Home Weight Monitoring for Infants

NCT04384276
View directory record Official record
Conditions
Cleft Lip and Palate
Interventions
The Weigh Easy System, Retrospective Control
Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
Up to 12 Weeks
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Oct 21, 2026, 7:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis

NCT04568980
View directory record Official record
Conditions
Cystic Fibrosis, Contraception
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
562 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
10
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Not applicable Interventional

Infant Study of Inhaled Saline in Cystic Fibrosis

NCT00709280
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS)
Drug
Lead sponsor
CF Therapeutics Development Network Coordinating Center
Network
Eligibility
4 Months to 59 Months
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Not applicable Interventional

Exercise Training Study for Patients With Cystic Fibrosis

NCT00609050
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Self-Regulated Exercise with Telephone Reinforcement, Standard Treatment, Qualitative Approach
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
10 Years to 18 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2016 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Lactation Success in Mothers of Critically Infants

NCT04097860
View directory record Official record
Conditions
Breast Pumping
Interventions
Text message including biomarker of breast pumping adequacy
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
122 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 21, 2026, 7:32 PM EDT
Completed No phase listed Observational

A Study to Evaluate Infants With Potential Exposure to Tanezumab Before Birth

NCT01362660
View directory record Official record
Conditions
Infant Developmental Assessment
Interventions
Unintentional exposure in utero
Other
Lead sponsor
Pfizer
Industry
Eligibility
Up to 15 Months
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
8
States / cities
Tempe, Arizona • Wildomar, California • Cutler Bay, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Antenatal Phenobarbital to Prevent Neonatal Intracranial Hemorrhage

NCT00009620
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Intracranial Hemorrhages
Interventions
Phenobarbital, Saline
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Female only
Enrollment
610 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1993 – 1997
U.S. locations
11
States / cities
Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 21, 2026, 7:32 PM EDT
Completed Phase 4 Interventional Results available

Population Pharmacokinetics of Prolonged Infusion Meropenem in Cystic Fibrosis (CF) Children

NCT01429259
View directory record Official record
Conditions
Cystic Fibrosis, Pneumonia, Pseudomonas Aeruginosa Infection
Interventions
meropenem
Drug
Lead sponsor
Joseph Kuti
Other
Eligibility
6 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Hartford, Connecticut • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 21, 2026, 7:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Volatile Organic Compounds in Cystic Fibrosis

NCT01379040
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
Cystic Fibrosis patients
Other
Lead sponsor
Landon Pediatric Foundation
Other
Eligibility
1 Year to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2014 · Synced Oct 21, 2026, 7:32 PM EDT
Terminated Phase 1Phase 2 Interventional

PEEP and V/Q Mismatch in Premature Infants

NCT03109613
View directory record Official record
Conditions
Respiratory Insufficiency Syndrome of Newborn, Infant, Premature, Diseases
Interventions
Positive end-expiratory pressure (PEEP)
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
0 Days to 28 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Newark, Delaware • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 21, 2026, 7:32 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

NCT05371613
View directory record Official record
Conditions
Mucopolysaccharidosis II
Interventions
tividenofusp alfa, idursulfase
Drug
Lead sponsor
Denali Therapeutics Inc.
Industry
Eligibility
2 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Oakland, California • Chicago, Illinois • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 7:32 PM EDT
Recruiting Not applicable Interventional

Simulation Trial of Telemedical Support for Paramedics

NCT06441760
View directory record Official record
Conditions
Emergencies, Cardiopulmonary Arrest, Acute Respiratory Failure, Status Epilepticus
Interventions
Video teleconsultation, Audio support
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 21, 2026, 7:32 PM EDT